Andreas M. Kaufmann (Germany)

Laboratory of Tumour Immunology, Clinic for Gynecology, Campus Benjamin Franklin Charite-Universitätsmedizin Berlin corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health

Andreas Kaufmann holds a degree in Biology from the University of Heidelberg (1992) and received a PhD at the German Cancer Centre working on tumour metastasis and EGF receptor signalling. In 1994, he proceeded to Loyola University at Chicago to join the Lab of Lutz Gissmann and started working on Human Papillomavirus immunology and therapeutic vaccine development. In 1997, he moved to Jena, Germany, and engaged in clinical testing of experimental vaccines and characterization of immune responses to HPV vaccination. Several clinical vaccination studies were performed. The research group moved to Berlin by the end of 2004. Andreas Kaufmann holds a position as head of research at the Department of Gynaecology of the Charité-Universitätsmedizin Berlin, Germany, since 2005. He is responsible for the development and organisation of the departmental research. This comprises acquisition and organisation of clinical studies with companies and academic translational basic research. The main interests are i) characterization of tumour-specific immune Responses and development and evaluation of tumour vaccination strategies ii) epidemiology of Human Papillomavirus (HPV) and cervical cancer and development and introduction of Screening methods, iii) cancer stem cell biology and targeted treatment.Throughout his career, he has been engaged in undergraduate, graduate, and postgraduate teaching and thesis supervision. Current interests are T cell immunology of HPV vaccination of both prophylactic and therapeutic approaches. Sensitive T cell assays have been developed and are validated for use in clinical studies. HPV testing is performed for diagnostic purposes on patients and subjects recruited into studies. HPV gene expression in correlation to disease progression is investigated to identify potential progression markers. In addition the biologic and immunologic features of cancer stem cells of HPV-related cervical and head-and-neck cancer are investigated. The emphasis is on translational research making innovative methods and therapies available to patients.

Presenter of 2 Presentations

Conference Calendar

Workshop 3: New Technologies Hall D

Multiplexed technologies (ID 73)

Session Date

07/20/2020

Session Time

13:30 - 14:55

Room

Hall D

Session Type

Basic Science

Session Name

Workshop 3: New Technologies

Lecture Time

13:30 - 13:30

Presenter

Andreas M. Kaufmann (Germany)

Authors

Andreas M. Kaufmann (Germany)

Clinical Research / HPV Diagnostics and Biomarkers for Early Detection and Prognosis of HPV-related Cancers ePoster

MULTIPLEXED MOLECULAR PROFILING BY QUANTIGENE 2.0 FROM PRIMARY CERVICAL SMEAR SAMPLES DETECTS DYSPLASIA WITH HIGH PRECISION (ID 960)

Session Date

07/21/2020

Session Time

10:00 - 17:00

Room

ePoster

Session Type

Poster Viewing - 20-24 July

Session Name

Clinical Research / HPV Diagnostics and Biomarkers for Early Detection and Prognosis of HPV-related Cancers

Lecture Time

10:18 - 10:19

Presenter

Andreas M. Kaufmann (Germany)

Authors

Abstract

Abstract

Introduction

Persistent infection by Human Papillomaviruses (HPV) is characterized by viral oncogene expression and upregulation of cellular proteins that can be regarded as biomarkers for transformation. The oncoproteins E6 and E7 have pleiotropic effects and interact with cellular proteins regulating proliferation, tumor suppressors, (cancer) stem cell markers, and tumor markers. The strength of expression correlates to dysplasia stage and progression.

Methods

A multiplexed mRNA quantifying assay based on Luminex/QuantiGene 2.0 technology platform (Thermo Fisher Scientific) was developed. It combines detection of the E7 oncogene of 18 HPV genotypes and 18 cellular biomarker expression, routinely used for diagnosis, markers for cancer stem cells, tumor markers and housekeeping genes for normalization. All mRNA species are detected simultaneously from a crude lysate of a cervical smear sample taken into Thinprep/PreserveCyte. In a prospective trial 1400 consecutively collected samples were measured and data used for logistic regression and ROC analyses.

Results

The assay has a high sensitivity detecting less than 40 CaSki or HeLa cells. It genotypes 18 HR-HPVs and detects leading types in multiple infections with highest E7 expression. Logistic regression identified E7 expression strength as most informative biomarker discriminating low grade and high grade (CIN2+) dysplasia. P16, proliferation associated markers (Ki67, MCM2, Stathmin), and tumor markers (ALDH1A1, BIRC5, hTERT) contributed to detection and differentiation of dysplastic stages. Accuracy by ROC analysis to detect CIN3+ from the initial screening sample was 90%.

Conclusions

Multiplexed mRNA quantification of viral and cellular biomarkers by QuantiGene 2.0 Plex assay detects HPV infection and dysplasia with high accuracy. The assay could be used as a triage to colposcopy after primary HPV screening. The assay procedure is simple and robust and maybe used in LMIC settings to reduce further triage and avoid overreferral.

Hide

Moderator of 1 Session

Conference Calendar

Clinical Science Oral Session

00570 - Oral Session 2: Cervical/Anal Screening and Management (ID 73)

Session Type

Clinical Science Oral Session

Session Date

07/21/2020

Session Time

15:00 - 15:50

Room

Hall C

Chair(s)

Watch Stream
Session Webcast

Session Webcast

[{"name":"VALIDATION OF A QUANTIGENE-HPV CERVICAL DISEASE-SCREENING TEST USING RT-QPCR \u003Csmall\u003E(ID 835)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":835,"presentation":"VALIDATION OF A QUANTIGENE-HPV CERVICAL DISEASE-SCREENING TEST USING RT-QPCR \u003Csmall\u003E(ID 835)\u003C\/small\u003E","session":"Oral Session 2: Cervical\/Anal Screening and Management","presenter":"Anna S. Skof (Germany)","photo":""},"playlist":[{"name":"VALIDATION OF A QUANTIGENE-HPV CERVICAL DISEASE-SCREENING TEST USING RT-QPCR","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/73\/835 Anna Skof.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/73\/835 Anna Skof.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/73\/93F7BE57.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/73\/835 Anna Skof.vtt"}]},{"name":"PERFORMANCE OF A NEW ONCOPROTEIN E6\/E7 TEST TO DETECT CIN3+ WITHIN THE ESTAMPA STUDY \u003Csmall\u003E(ID 1290)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1290,"presentation":"PERFORMANCE OF A NEW ONCOPROTEIN E6\/E7 TEST TO DETECT CIN3+ WITHIN THE ESTAMPA STUDY \u003Csmall\u003E(ID 1290)\u003C\/small\u003E","session":"Oral Session 2: Cervical\/Anal Screening and Management","presenter":"Maribel Almonte (France)","photo":""},"playlist":[{"name":"Maribel Almonte - IPVC20 - 1290 - PERFORMANCE OF A NEW ONCOPROTEIN E6E7 TEST TO DETECT CIN3 WITHIN T","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/73\/Maribel Almonte - IPVC20 - 1290 - PERFORMANCE OF A NEW ONCOPROTEIN E6E7 TEST TO DETECT CIN3 WITHIN THE ESTAMPA STUDy -2-.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/73\/Maribel Almonte - IPVC20 - 1290 - PERFORMANCE OF A NEW ONCOPROTEIN E6E7 TEST TO DETECT CIN3 WITHIN THE ESTAMPA STUDy -2-.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/73\/B41CAFD9.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/73\/Maribel Almonte - IPVC20 - 1290 - PERFORMANCE OF A NEW ONCOPROTEIN E6E7 TEST TO DETECT CIN3 WITHIN THE ESTAMPA STUDy -2-.vtt"}]},{"name":"DISTINCT ANAL CANAL MICROBIOME IS CORRELATED WITH HSIL IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN \u003Csmall\u003E(ID 436)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":436,"presentation":"DISTINCT ANAL CANAL MICROBIOME IS CORRELATED WITH HSIL IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN \u003Csmall\u003E(ID 436)\u003C\/small\u003E","session":"Oral Session 2: Cervical\/Anal Screening and Management","presenter":"Joel M. Palefsky (United States of America)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/37.jpg"},"playlist":[{"name":"DISTINCT ANAL CANAL MICROBIOME IS CORRELATED WITH HSIL IN HIV-POSITIVE MEN WHO HAVE SEX WITH MEN","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/73\/GMT20200604-144629_Joel-Palef_1760x900.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/73\/GMT20200604-144629_Joel-Palef_1760x900.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/73\/EB2584C7.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/73\/GMT20200604-144629_Joel-Palef_1760x900.vtt"}]},{"name":"VALIDATION OF HOST CELL DNA METHYLATION MARKERS FOR CANCER RISK STRATIFICATION OF HIGH-GRADE ANAL INTRAEPITHELIAL NEOPLASIA IN HIV-POSITIVE MEN \u003Csmall\u003E(ID 249)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":249,"presentation":"VALIDATION OF HOST CELL DNA METHYLATION MARKERS FOR CANCER RISK STRATIFICATION OF HIGH-GRADE ANAL INTRAEPITHELIAL NEOPLASIA IN HIV-POSITIVE MEN \u003Csmall\u003E(ID 249)\u003C\/small\u003E","session":"Oral Session 2: Cervical\/Anal Screening and Management","presenter":"Ramon P. Van der Zee (Netherlands)","photo":""},"playlist":[{"name":"VALIDATION OF HOST CELL DNA METHYLATION MARKERS FOR CANCER RISK STRATIFICATION OF HIGH-GRADE ANAL IN","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/73\/249.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/73\/249.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/73\/A551CC2D.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/73\/249.vtt"}]}]